X Genomics Inc (TXG) stock saw a decline, ending the day at $14.84 which represents a decrease of $-0.01 or -0.07% from the prior close of $14.85. The stock opened at $14.99 and touched a low of ...

CEO Serge Saxonov, PhD, says provider of single cell, spatial, and in situ instruments expects to see benefits from sales ...

In a report released today, Michael Ryskin from Bank of America Securities maintained a Hold rating on 10x Genomics (TXG – Research Report).

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Analysts have set 12-month price targets for 10x Genomics, revealing an average target of $19.67, a high estimate of $28.00, ...

X Genomics Inc (TXG) stock saw a decline, ending the day at $14.9 which represents a decrease of $-1.41 or -8.65% from the prior close of $16.31. The stock opened at $16.1 and touched a low of $14.19 ...

Weiss Ratings reaffirmed their sell (e+) rating on shares of 10x Genomics (NASDAQ:TXG – Free Report) in a report released on Saturday,Weiss Ratings reports. TXG has been the subject of several other ...

Genomics (TXG – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Ryskin from ...

"Our team delivered solid sequential revenue growth over last quarter," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "We are confident the work we've done throughout 2024 sets us up ...

10x Genomics excels in single-cell and spatial technologies but faces significant challenges. Despite an EPS beat, revenue fell 1% due to sales disruption and competitive pricing. The company's ...

Across the recent three months, 6 analysts have shared their insights on 10x Genomics (NASDAQ:TXG), expressing a variety of opinions spanning from bullish to bearish. The table below summarizes ...